The American Society of Clinical Oncology and the College of American Pathologists released guidelines urging all women with invasive breast cancer to be screened for the human epidermal growth factor receptor 2 gene and protein. Women with HER2-positive cancer should get HER2-targeted therapies, and those treatments should be not used for HER2-negative cancers, according to the guidelines published in the Journal of Clinical Oncology and the Archives of Pathology & Laboratory Medicine.

Full Story:
HealthDay News

Related Summaries